Serum Resistin as a Biological Marker for Coronary Artery Disease and Restenosis in Type 2 Diabetic Patients

Abstract

BackgroundResistin is an adipocyte-secreted hormone. The relationship between circulating resistin concentrations and atherosclerotic coronary artery disease (CAD) in type 2 diabetic patients, if any, remains poorly understood. Serum resistin concentrations were investigated in type 2 diabetic patients with CAD (DMCAD), and compared with the concentrations in diabetics patients without CAD (diabetes mellitus, DM). Whether resistin levels are associated with increased restenosis rates in diabetic patients with CAD after successful coronary stenting was also investigated. Methods and Results Fasting serum resistin, adiponectin, and leptin concentrations were measured in 45 DMCAD patients and 47 DM controls. The percutaneous coronary intervention study included 70 DMCAD patients, who underwent elective and successful coronary bare metal stent (BMS) implantation for the treatment of de novo lesions. Serum resistin concentrations were higher in the DMCAD patients than in the DM controls (5.75±3.21 vs 2.53±2.47 ng/ml, mean ± SEM, p<0.001), and these differences were persistent regardless of age or body mass index. Insulin resistance indices, as assessed via homeostasis model assessment (HOMA-IR) correlated significantly with resistin concentrations (r=0.4, p<0.001). Resistin was an independent factor, and was associated with DMCAD in the multivariate analysis. In the percutaneous coronary intervention study, HOMA-IR was not associated with subsequent restenosis rates after BMS implantation in DMCAD patients. Pre-procedural serum resistin concentrations were higher in restenosis group than in the patients without restenosis. Conclusions Serum resistin may prove to be a useful biological marker for CAD and restenosis in patients with type 2 DM. (Circ J 2007; 71: 868 -873)

Resistin predicts ischemia in myocardial perfusion scintigraphy

“…Hoefle et al were in agreement with the last 2 authors and reported no significant increase in plasma resistin levels in coronary stenosis (14). On et al found higher resistin levels in CAD in type 2 diabetes mellitus (15). In another study, the severity of CAD was represented as the number of stenoses in coronaries.…”

Serum Resistin Levels and Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

“…In vitro, resistin was reported to promote human smooth muscle cell proliferation 8) ; therefore, resistin may play a role in the development of restenosis associated with neointimal proliferation. Recently, On et al 18) reported resistin levels to be higher in 35 diabetic patients who developed restenosis than in 35 diabetic patients who did not 18) ; however, no correlation was found between Kaplan-Meier analysis demonstrated a lower event-free survival rate in patients with a resistin level of 4.0 ng/mL than in those without (p 0.001). resistin levels and the severity of restenosis.…”

Association of serum omentin-1 levels with coronary artery disease

“…In addition, Yamawaki et al demonstrated a vasodilating effect of omentin on isolated blood vessels, suggesting omentin involvement in endothelial function [14] . There have been several reports showing that other adipokines, such as adiponectin [15][16][17] , resistin [17][18][19][20] , leptin [19] , visfatin [21][22][23] , TNF-α [24] , and IL-6 [25] , are related to inflammation and coronary artery disease (CAD). We hypothesized that omentin-1 might be implicated in CAD due to a possible association with inflammation and endothelial function.…”